Swiss biotech company Novimmune and South Korean-based LegoChem Biosciences (LCB) have entered a research collaboration to evaluate an antibody drug conjugate candidate.

LCB has been developing partnerships worldwide through the potential of its ADC platform technology.

The company out-licensed an anti-Her2-ADC molecule to Fosun Pharma in 2015.

In January this year, a research licensing deal was signed with Takeda in a bid to evaluate next-generation ADC candidates.

Novimmune chairman and CEO Eduard Holdener said: “Our antibody expertise, married with LCB’s proprietary ADC technology, supports our quest to provide better options to cancer patients.”

"Our antibody expertise, married with LCB’s proprietary ADC technology, supports our quest to provide better options to cancer patients."

ADCs only target cancer cells and spare healthy cells, and are molecules composed of a tumour specific monoclonal antibody linked to a cytotoxic agent.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Last month, Novimmune and Tiziana Life Sciences (TILS) had signed a second collaboration agreement, as part of which the latter secured exclusive rights to develop and commercialise its anti-IL-6R monoclonal antibody, NI-1201.

Tiziana proposes to explore the development of the antibody in non-alcoholic steato hepatitis (NASH), diabetes and other life threatening inflammatory diseases, as well as foralumab (NI-0401).

Novimmune focuses on the discovery and development of antibody-based drugs, and is engaged in the field of targeted therapies with its anti-CD47 / anti-CD19 and anti-CD47 / anti-mesothelin bispecific antibodies that bind to hematological and solid tumours, respectively.

The company aims to develop drugs for the targeted treatment of inflammatory diseases, immune-related disorders, as well as cancer.